POM-V Prescription Required Companion Animal

Robexera 20 mg/ml Solution for Injection for Cats and Dogs

Active ingredient: Robenacoxib

Form

Injection

Species

Cats Dogs

Manufacturer

KRKA, d.d., Novo mesto

VMD MA No.

01656/3117

What it's used for

For the treatment of pain and inflammation associated with soft tissue surgery.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Robenacoxib

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Robexera 20 mg/ml Solution for Injection for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the treatment of pain and inflammation associated with soft tissue surgery.

The recommended dose is 2 mg robenacoxib/kg body weight (1 mL of the veterinary
medicinal product per 10 kg body weight).
Administer the veterinary medicinal product approximately 30 minutes before the
start of surgery, for example around the time of induction of general anaesthesia.
After surgery in cats, once daily treatment may be continued at the same dosage and
at the same time every day for up to 2 days.
After soft tissue surgery in dogs, once daily treatment may be continued at the same
dosage and at the same time every day for up to 2 days.
The interchangeable use of the veterinary medicinal products containing robenacoxib
in the form of tablets and solution for injection has been tested in target animal safety
studies and was shown to be well tolerated by cats and dogs.
The veterinary medicinal products containing robenacoxib in the form of solution for
injection or tablets may be used interchangeably in accordance with the indications
and directions of use approved for each pharmaceutical form. Treatment should not
exceed one dose (either tablet or injection) per day. Please note that the
recommended doses for the two formulations may be different.
The stopper should be subjected to a maximum of 16 piercings.

Do not use in animals suffering from gastrointestinal ulceration.
AN: 01948/2024 & 01952/2024
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory
drugs (NSAIDs).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
See also section 3.7.

Cats:
Common
(1 to 10 animals / 100 animals
treated):
Injection site pain
Digestive tract disorder
, Diarrhoea
, Vomiting
Uncommon
(1 to 10 animals / 1 000
animals treated):
Bloody diarrhoea, Blood in vomit
Most cases were mild and recovered without treatment.
AN: 01948/2024 & 01952/2024
Dogs:
Common
(1 to 10 animals / 100 animals
treated):
Injection site pain
Digestive tract disorder
, Diarrhoea
, Vomiting
Uncommon
(1 to 10 animals / 1 000
animals treated):
Tarry stool
Decreased appetite
Moderate or severe pain at injection site was uncommon.
Most cases were mild and recovered without treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in cats less
than 4 months of age and in dogs less than 2 months of age, or in cats or dogs less
than 2.5 kg body weight.
Use in animals with impaired cardiac, renal or hepatic function or those are
dehydrated, hypovolaemic or hypotensive may involve additional risks. If use cannot
be avoided, these animals require careful monitoring and fluid therapy.
Use this veterinary medicinal product under strict veterinary monitoring in cases at
risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to
other NSAIDs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
For pregnant women, particularly near-term pregnant women, accidental injection
and prolonged dermal exposure increases the risk for premature closure of the
ductus arteriosus in the foetus.
Wash hands and exposed skin immediately after use of the veterinary medicinal
product.
In case of accidental oral exposure (hand-to-mouth), prolonged dermal exposure or
self-injection, seek medical advice immediately and show the package leaflet or the
label to the physician.
Special precautions for the protection of the environment:
Not applicable.

This veterinary medicinal product must not be administered in conjunction with other
NSAIDs or glucocorticosteroids. Pre-treatment with other anti-inflammatory
medicines may result in additional or increased adverse effects and accordingly a
treatment-free period with such substances should be observed for at least 24 hours
before the commencement of treatment with this veterinary medicinal product. The
treatment-free period, however, should take into account the pharmacokinetic
properties of the veterinary medicinal products used previously.
Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics
or angiotensin-converting enzyme (ACE) inhibitors, should be subject to clinical
monitoring.
In healthy cats or dogs treated with or without the diuretic furosemide, concomitant
administration of this veterinary medicinal product with the ACE inhibitor benazepril
for 7 days was not associated with any negative effects on plasma (cats) or urine
(dogs) aldosterone concentrations, plasma renin activity or glomerular filtration rate.
No safety data in the target population and no efficacy data in general exist for the
combined treatment of robenacoxib and benazepril.
AN: 01948/2024 & 01952/2024
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy during
surgery should be considered to decrease potential renal complications when using
NSAIDs peri-operatively.
Concurrent administration of potentially nephrotoxic medicines should be avoided as
there might be an increased risk of renal toxicity.
Concurrent use of other active substances that have a high degree of protein binding
may compete with robenacoxib for binding and thus lead to toxic effects.

Store in a refrigerator (2 °C – 8 °C).
After first broaching the vial, store at temperature below 25 °C.
Store in the original package in order to protect from light.

Not applicable.
AN: 01948/2024 & 01952/2024
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.